BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9193748)

  • 1. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation.
    Kawanishi Y; Passweg J; Drobyski WR; Rowlings P; Cook-Craig A; Casper J; Pietryga D; Garbrecht F; Camitta B; Horowitz M; Juckett M; Margolis D; Flomenberg N; Keever-Taylor CA
    Bone Marrow Transplant; 1997 Jun; 19(11):1069-77. PubMed ID: 9193748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors.
    Pabst C; Schirutschke H; Ehninger G; Bornhäuser M; Platzbecker U
    Clin Cancer Res; 2007 May; 13(10):2916-22. PubMed ID: 17504991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
    Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
    Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors.
    Cela ME; Holladay MS; Rooney CM; Richardson S; Alexander B; Krance RA; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1996 Feb; 17(2):243-7. PubMed ID: 8640174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
    Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
    Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis.
    Marciniak E; Romond EH; Thompson JS; Henslee PJ
    Bone Marrow Transplant; 1988 Nov; 3(6):589-98. PubMed ID: 3063328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study.
    Fleming DR; Henslee-Downey PJ; Romond EH; Harder EJ; Marciniak E; Munn RK; Messino MJ; Macdonald JS; Bishop M; Rayens MK; Thompson JS; Foon KA
    Bone Marrow Transplant; 1996 Jun; 17(6):917-22. PubMed ID: 8807094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
    Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
    J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors.
    Löwenberg B; Wagemaker G; van Bekkum DW; Sizoo W; Sintnicolaas K; Hendriks WD; Hagenbeek A
    Bone Marrow Transplant; 1986 Dec; 1(2):133-40. PubMed ID: 3332128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia.
    Drobyski WR; Pelz C; Kabler-Babbitt C; Hessner M; Baxter-Lowe LA; Keever-Taylor CA
    Biol Blood Marrow Transplant; 1998; 4(1):3-12. PubMed ID: 9701386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34(+) cell dose.
    Keever-Taylor CA; Klein JP; Eastwood D; Bredeson C; Margolis DA; Burns WH; Vesole DH
    Bone Marrow Transplant; 2001 Apr; 27(8):791-800. PubMed ID: 11477435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation.
    Gajewski J; Gjertson D; Cecka M; Tonai R; Przepiorka D; Hunt L; Giralt S; Chan KW; Feig S; Territo M; Andersson B; van Besien K; Khouri I; Fischer H; Babbitt L; Ippolitti C; Schiller G; Lill M; Warkentin D; Neumann J; Petz L; Terasaki P; Champlin R
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):76-82. PubMed ID: 9267667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.